Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics reports 2023 net income of $12.7 million versus 2022 net loss

Positive Impact 4 of 5 earnings Written later

TG Therapeutics reported fourth quarter and full year 2023 results, furnished as Exhibit 99.1 to a Form 8-K. Full-year total revenue was $233.7 million, including a $140.0 million one-time payment from Neuraxpharm, and the company swung to net income of $12.7 million from a $198.3 million net loss in 2022. The company also set a 2024 BRIUMVI U.S. net product revenue target of $220 million to $260 million, giving shareholders a benchmark for future results.

Key points

  • Q4 2023 total revenue was $44.0 million versus $80 thousand in Q4 2022; Q4 net loss narrowed to $14.4 million from $53.0 million.
  • Full-year 2023 BRIUMVI U.S. net product revenue was $88.8 million; license, milestone and other revenue was $141.7 million, mainly from the $140.0 million Neuraxpharm payment received in July 2023.
  • 2024 targets: BRIUMVI U.S. net product revenue of approximately $220 million to $260 million and total operating expense of approximately $250 million.
  • Year-end 2023 cash, cash equivalents and investment securities were $217.5 million.

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECFeb 28, 2024, 7:24 AM ET
Accession number0001437749-24-005802

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 28, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.